

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Elzonris (tagraxofusp-erzs)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Elzonris (tagraxofusp-erzs) injection

APPROVAL CRITERIA

Requests for Elzonris (tagraxofusp-erzs) may be approved if the following criteria are met:

- I. Individual is 2 years of age or older; **AND**
- II. Individual has a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN); **AND**
- III. Individual has a current Eastern Cooperative Oncology Group (ECOG) status of 0-1; **AND**
- IV. Individual is using as monotherapy; **AND**
- V. At initial therapy, individual has a baseline serum albumin of 3.2 g/dL or higher (NCCN 2A).

Requests for Elzonris (tagraxofusp-erzs) may not be approved when the above criteria are not met and for all other indications.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2209. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 14, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Elzonris [Package Insert]. New York, NY. Stemline Therapeutics, Inc.; 2018
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.

CRX-ALL-0540-20

PAGE 1 of 2 04/21/2020
New Program Date 05/21/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

6. NCCN Clinical Practice Guidelines in Oncology™. © 2020 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on January 14, 2020.
- a. Acute Myeloid Leukemia. V3.2020. Revised December 23, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.